AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27373347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal upstage in invasive lobular subtype
Number of subjects: 250
Study 25158633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya yoga (active group, n = 11)
Number of subjects: 21
Study 25158633 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (control group, n = 10)
Number of subjects: 21
Study 22268365 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (overall treatment)
Number of subjects: 52
Study 18091016 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA (3 g)
Number of subjects: 11
Study 18091016 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA + Resistance Exercise (EX-GABA)
Number of subjects: 11
Study 18091016 — intervention group
Group type: COMPARATOR
Intervention: Resistance Exercise (EX-P)
Number of subjects: 11
Study 16896048 — intervention group
Group type: EXPERIMENTAL
Intervention: Median ovarian volume >or=3.0 cm3
Number of subjects: 0
Study 14658966 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose divalproex sodium
Number of subjects: 71
Study 10758465 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous and pulmonary artery catheterization performed awake using local anaesthesia
Number of subjects: 20
Study 10758465 — intervention group
Group type: COMPARATOR
Intervention: Central venous and pulmonary artery catheterization after induction of general anaesthesia
Number of subjects: 20
Study 9065315 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of verapamil (Veramex 40)
Number of subjects: 16
Study 9065315 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation of verapamil
Number of subjects: 16
Study 1557803 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 50
Study 1557803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution
Number of subjects: 50
Study 1557803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 2860033 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta Loop
Number of subjects: 246
Study 2860033 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta T
Number of subjects: 246
Study 31918437 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom nutrition education program
Number of subjects: 0
Study 30231098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolder bar attachments (BOD)
Number of subjects: 90
Study 30231098 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator attachments (LOD)
Number of subjects: 90
Study 30231098 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient telescopic attachments (TOD)
Number of subjects: 90
Study 30231098 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study 30231098 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 26625270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 427
Study 26625270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 26625270 — intervention group
Group type: COMPARATOR
Intervention: Placebo/pioglitazone
Number of subjects: 427
Study 23905576 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled GS-9411 (2.4, 4.8, and 9.6 mg), dosed twice daily for 14 days
Number of subjects: 36
Study 23905576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23905576 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled GS-9411
Number of subjects: 36
Study 21926426 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (ER) 37.5 to 300 mg/day
Number of subjects: 0
Study 21926426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20534179 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 2183
Study 20534179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2183
Study 18824828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d
Number of subjects: 285
Study 18824828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 285
Study 18824828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 16874755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 202
Study 16874755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 12952496 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 2‐093 (20, 50, 100, 200, 400, 600, 900, 1200 mg)
Number of subjects: 64
Study 12952496 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 2‐093
Number of subjects: 64
Study 12952496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10648452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 14
Study 10648452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9007129 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 185 mg/m2 and Carboplatin 350 mg/m2
Number of subjects: 24
Study 1891611 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted reinforcement of instruction
Number of subjects: 52
Study 1891611 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction in avoidance measures (Control)
Number of subjects: 52
Study 6671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation at 0 payment
Number of subjects: 65
Study 6671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation at 25 payment
Number of subjects: 65
Study 6671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation at 50 payment
Number of subjects: 65
Study 6671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Task difficulty: decreasing
Number of subjects: 65
Study 6671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Task difficulty: increasing
Number of subjects: 65
Study 6671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Training duration: three days
Number of subjects: 65
Study 29563072 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMBER-K (Ketamine + TIMBER therapy)
Number of subjects: 20
Study 29563072 — intervention group
Group type: COMPARATOR
Intervention: TIMBER-P (Placebo + TIMBER therapy)
Number of subjects: 20
Study 27295296 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual trigger point compression therapy
Number of subjects: 12
Study 27295296 — intervention group
Group type: COMPARATOR
Intervention: Manual sham therapy
Number of subjects: 12
Study 24978857 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine with 3.75 μg antigen
Number of subjects: 330
Study 24978857 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine with 7.5 μg antigen
Number of subjects: 330
Study 24978857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted vaccine with 15 μg antigen (for children 12-35 months only)
Number of subjects: 330
Study 24978857 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of MF59-adjuvanted seasonal influenza vaccine
Number of subjects: 330
Study 24978857 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 330
Study 22629160 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Labor Epidural Analgesia (CLEA)
Number of subjects: 92
Study 22629160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Labor Epidural Analgesia (ILEA)
Number of subjects: 92
Study 22629160 — intervention group
Group type: COMPARATOR
Intervention: Febrile group (temperature ≥ 38 °C)
Number of subjects: 92
Study 22629160 — intervention group
Group type: COMPARATOR
Intervention: Afebrile group (temperature < 38 °C)
Number of subjects: 92
Study 19878450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep (S)
Number of subjects: 108
Study 19878450 — intervention group
Group type: COMPARATOR
Intervention: Sleep Deprivation (SD)
Number of subjects: 108
Study 19878450 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Sleep
Number of subjects: 108
Study 16706150 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychromatic visible + IR polarized light (480‐3400 nm, 12 J/cm2)
Number of subjects: 0
Study 16706150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 14576376 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Stroke Unit Service (ESUS)
Number of subjects: 320
Study 14576376 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Stroke Unit Service (OSUS)
Number of subjects: 320
Study 10794804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron 1 mg twice daily
Number of subjects: 230
Study 10794804 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine 10 mg sustained release capsule twice daily
Number of subjects: 230
Study 8989127 — intervention group
Group type: EXPERIMENTAL
Intervention: hBNP infusion (0.003, 0.01, 0.03, and 0.1 microgram/kg per minute)
Number of subjects: 20
Study 8989127 — intervention group
Group type: EXPERIMENTAL
Intervention: hBNP infusion
Number of subjects: 20
Study 1295444 — intervention group
Group type: EXPERIMENTAL
Intervention: FPEPIR regimen (CDDP + 5-FU + 4'-epirubicin)
Number of subjects: 60
Study 1295444 — intervention group
Group type: COMPARATOR
Intervention: FP regimen (CDDP + 5-FU)
Number of subjects: 60
Study 1295444 — intervention group
Group type: EXPERIMENTAL
Intervention: FPEPIR regimen
Number of subjects: 60
Study 1295444 — intervention group
Group type: COMPARATOR
Intervention: FP regimen
Number of subjects: 60
Study 3881574 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 25 mg
Number of subjects: 164
Study 3881574 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 164
Study 3881574 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 164
Study 3881574 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 164
Study 30249940 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with atorvastatin and amlodipine
Number of subjects: 68
Study 30249940 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 31494531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients
Number of subjects: 91
Study 31494531 — intervention group
Group type: COMPARATOR
Intervention: Nonmalignant pulmonary diseases
Number of subjects: 91
Study 31494531 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 91
Study 31494531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic model
Number of subjects: 91
Study 28411114 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biologically active adrenomedullin (bio-ADM) on day 1 (median [Q1-Q3], 110 [59-198] pg/mL)
Number of subjects: 956
Study 28411114 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-ADM trajectory during the first week of treatment
Number of subjects: 956
Study 28411114 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of bio-ADM below 110 pg/mL at day 7
Number of subjects: 956
Study 28411114 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-ADM concentration increase (OR [95% CI], 1.9 [1.4-2.5]; P < .0001)
Number of subjects: 956
Study 25627664 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives (up to £400 in shopping vouchers)
Number of subjects: 612
Study 25627664 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 612
Study 25627664 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 612
Study 22972239 — intervention group
Group type: EXPERIMENTAL
Intervention: Step frequency manipulation group (SFM)
Number of subjects: 24
Study 22972239 — intervention group
Group type: COMPARATOR
Intervention: Free step frequency group (SFF)
Number of subjects: 24
Study 21463150 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus CABG
Number of subjects: 1212
Study 21463150 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1212
Study 20029506 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 1000 mg.day(‐1) for 3 weeks
Number of subjects: 40
Study 20029506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17003304 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Profile (DSMP)
Number of subjects: 146
Study 17003304 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Behavior Rating Scale (DBRS)
Number of subjects: 146
Study 17003304 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of DSMP and DBRS
Number of subjects: 146
Study 15271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox 1% shampoo
Number of subjects: 203
Study 15271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.3% shampoo
Number of subjects: 203
Study 15271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.1% shampoo
Number of subjects: 203
Study 15271194 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 203
Study 11053509 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (200 mg ferrous sulfate)
Number of subjects: 191
Study 11053509 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly iron supplementation (2 x 200 mg ferrous sulfate)
Number of subjects: 191
Study 9008378 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups
Number of subjects: 0
Study 9008378 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0
Study 9008378 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 0
Study 9008378 — intervention group
Group type: COMPARATOR
Intervention: Individuals
Number of subjects: 0
Study 8292312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 16
Study 8292312 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no treatment)
Number of subjects: 16
Study 2979209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg, 6-hourly, n = 8)
Number of subjects: 30
Study 2979209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg, 6-hourly, n = 10)
Number of subjects: 30
Study 2979209 — intervention group
Group type: COMPARATOR
Intervention: No treatment (placebo, n = 12)
Number of subjects: 30
Study 2979209 — intervention group
Group type: COMPARATOR
Intervention: No treatment (gastric ulcer patients)
Number of subjects: 30
Study 28594747 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping Progrip mesh
Number of subjects: 274
Study 28594747 — intervention group
Group type: COMPARATOR
Intervention: Sutured polypropylene mesh (standard)
Number of subjects: 274
Study 27566642 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention (up to 13 scripted encounters with healthcare advisors)
Number of subjects: 641
Study 27566642 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 641
Study 25100538 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation group (EAG)
Number of subjects: 31
Study 25100538 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (STG)
Number of subjects: 31
Study 22243907 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention group
Number of subjects: 309
Study 22243907 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 309
Study 20139391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670
Study 20139391 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 50 mg twice-daily
Number of subjects: 670
Study 20139391 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 140 mg once-daily
Number of subjects: 670
Study 20139391 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 70 mg twice-daily
Number of subjects: 670
Study 20139391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily for 6 months without complete cytogenetic response
Number of subjects: 670
Study 18084015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily subcutaneously up to 8 days
Number of subjects: 2867
Study 18084015 — intervention group
Group type: COMPARATOR
Intervention: Usual care (placebo or unfractionated heparin)
Number of subjects: 2867
Study 18084015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2867
Study 18084015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux vs. placebo
Number of subjects: 2867
Study 18084015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux vs. UF heparin infusion for 24-48 h
Number of subjects: 2867
Study 16147905 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d) at bed-time
Number of subjects: 100
Study 16147905 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (160 mg/d) upon awakening
Number of subjects: 100
Study 12514271 — intervention group
Group type: EXPERIMENTAL
Intervention: HSAFA diet (high saturated fat diet; 38.4% E% from fat; P/S ratio = 0.14)
Number of subjects: 25
Study 12514271 — intervention group
Group type: COMPARATOR
Intervention: LSAFA diet (low saturated fat diet; 19.7% E% from fat; P/S = 0.17)
Number of subjects: 25
Study 12514271 — intervention group
Group type: EXPERIMENTAL
Intervention: HUFA diet (high content of mono- and polyunsaturated fatty acids; 38.2% E% from fat; P/S = 1.9)
Number of subjects: 25
Study 12514271 — intervention group
Group type: COMPARATOR
Intervention: LSAFA diet
Number of subjects: 25
Study 12514271 — intervention group
Group type: EXPERIMENTAL
Intervention: HSAFA diet
Number of subjects: 25
Study 10645371 — intervention group
Group type: EXPERIMENTAL
Intervention: High visuo-spatial working memory group
Number of subjects: 2
Study 10645371 — intervention group
Group type: COMPARATOR
Intervention: Concurrent tasks (verbal, visual, spatial-sequential, spatial-simultaneous)
Number of subjects: 2
Study 9032708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation Provocation Test (HVPT)
Number of subjects: 155
Study 9032708 — intervention group
Group type: COMPARATOR
Intervention: Placebo Test (PT, isocapnic overbreathing)
Number of subjects: 155
Study 1391736 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone (FZ) high dose, 2 week course
Number of subjects: 0
Study 1391736 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone (FZ)
Number of subjects: 0
Study 6120711 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16
Study 6120711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 16
Study 6120711 — intervention group
Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 16
Study 6120711 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 16
Study 31151239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital and infratrochlear nerve block with 8 mL of 0.5% ropivacaine
Number of subjects: 66
Study 31151239 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (Sham Block group)
Number of subjects: 66
Study 28845935 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine fumarate (1 g), acetyl-L-carnitine (0.5 g) twice daily, clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins A, E, C, selenium, zinc)
Number of subjects: 173
Study 28845935 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins)
Number of subjects: 173
Study 25721007 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND 2-4 intervention (n=104)
Number of subjects: 201
Study 25721007 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=97)
Number of subjects: 201
Study 24874591 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin + metformin
Number of subjects: 167
Study 24874591 — intervention group
Group type: COMPARATOR
Intervention: glimepiride + metformin
Number of subjects: 167
Study 18718771 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard saphenofemoral ligation (SSL)
Number of subjects: 182
Study 18718771 — intervention group
Group type: COMPARATOR
Intervention: Flush saphenofemoral ligation (FSL)
Number of subjects: 182
Study 15155403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RTUF)
Number of subjects: 282
Study 15155403 — intervention group
Group type: COMPARATOR
Intervention: RTUF supplement
Number of subjects: 282
Study 15155403 — intervention group
Group type: COMPARATOR
Intervention: Blended maize/soy flour
Number of subjects: 282
Study 15155403 — intervention group
Group type: COMPARATOR
Intervention: Maize/soy flour and RTUF supplement
Number of subjects: 282
Study 15155403 — intervention group
Group type: EXPERIMENTAL
Intervention: All children that reached WHZ >0
Number of subjects: 282
Study 11381581 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat design (n=20)
Number of subjects: 83
Study 11381581 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave design (n=20)
Number of subjects: 83
Study 11381581 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave design (n=25)
Number of subjects: 83
Study 11381581 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilised design (n=22)
Number of subjects: 83
Study 11381581 — intervention group
Group type: COMPARATOR
Intervention: All prosthetic designs
Number of subjects: 83
Study 11381581 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave design
Number of subjects: 83
Study 11381581 — intervention group
Group type: EXPERIMENTAL
Intervention: All implants
Number of subjects: 83
Study 9220214 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg/d, administered twice a day (BID)
Number of subjects: 120
Study 9220214 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg/d, administered three times a day (TID)
Number of subjects: 120
Study 9220214 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg BID
Number of subjects: 120
Study 9220214 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg TID
Number of subjects: 120
Study 8345495 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg) after 48 hours of abstention
Number of subjects: 0
Study 8345495 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 48 hours of abstention
Number of subjects: 0